Skip to content
DilutionScan

Reading SEC forms: 8-K, 6-K, 10-Q and more

8-K vs 10-K: Event Report Within Four Business Days or the Audited Annual Report

An 8-K reports one event within four business days; a 10-K is the audited, certified annual report. How they differ and how one event shows up in both.

7 min readLast verified

The short version

Form 8-KForm 10-K
What it isA current report on one or more specific eventsThe annual report on the whole fiscal year
TriggerAn event listed in the form's itemsThe end of the fiscal year
DeadlineGenerally four business days after the event60, 75 or 90 days after year end, by filer status
Financial statementsUsually none; an earnings release is unauditedAudited, with the independent auditor's report
Signed byOne authorized officerThe principal executive, financial and accounting officers and at least a majority of the board
Sarbanes-Oxley certificationsNoneExhibits 31 and 32
Filed or furnishedMostly filed; Items 2.02 and 7.01 are furnishedFiled
How many a yearAs many as events requireOne

An 8-K tells you something happened. A 10-K tells you, a few weeks after the year ends, what the whole year added up to, with an auditor's opinion on the numbers. The 8-K is fast and narrow. The 10-K is slow, complete and carries more legal weight.

The same event usually appears in both: first as an 8-K within days, then inside the 10-K's financial statements, notes and exhibit list. The individual 8-K items are covered in 8-K item codes explained; this guide is about how the two forms relate.

Event report versus periodic report

The 8-K is event-driven. Under General Instruction B.1 of Form 8-K, a report is due within four business days after an event listed in Sections 1 to 6 and 9 of the form, unless an item says otherwise. If nothing in the list happens, no 8-K is required.

The 10-K is periodic. Exchange Act Rule 13a-1 requires an annual report for each fiscal year, and General Instruction A of Form 10-K sets the deadline: 60 days after the fiscal year end for large accelerated filers, 75 days for accelerated filers and 90 days for everyone else. The 10-Q and 10-K deadlines table shows which companies fall into which group. The quarterly 10-Q sits between the two. Under General Instruction B.3 of Form 8-K, information already reported does not need to be reported again on an 8-K.

Audited, certified and signed

What separates the 10-K most clearly is the checking behind it.

  • Audited financial statements. Item 8 of Form 10-K requires financial statements meeting Regulation S-X, which for annual statements means an audit and a report from an independent registered public accounting firm. An 8-K earnings release under Item 2.02 is normally unaudited.
  • Signatures. General Instruction D(2)(a) of Form 10-K requires signatures from the registrant's principal executive officer, principal financial officer, controller or principal accounting officer, and at least a majority of the board. An 8-K is signed on behalf of the registrant by one duly authorized officer.
  • Certifications. Rule 13a-14 requires the principal executive and principal financial officers to sign certifications filed as exhibits to every 10-K and 10-Q. These are the Sarbanes-Oxley Section 302 and 906 certifications, filed as Exhibits 31 and 32. An 8-K carries neither.

Part III of a 10-K (directors, executive pay, ownership, related transactions and auditor fees) may be left out and incorporated by reference from the proxy statement, but only if that proxy is filed within 120 days after the fiscal year end, under General Instruction G(3). Otherwise the information must arrive in the 10-K or an amendment by the end of that 120-day period.

Filed versus furnished

General Instruction B.2 of Form 8-K says information furnished under Item 2.02 (results of operations) or Item 7.01 (Regulation FD) is not deemed "filed" for purposes of Section 18 of the Exchange Act, unless the company says otherwise or incorporates it by reference into another filing. Section 18 is the provision that creates liability for false or misleading statements in filed documents.

So the earnings press release attached to an Item 2.02 8-K is furnished, while the audited statements in the 10-K are filed. The release often comes first and the numbers usually match, but the 10-K is the one the company files as its financial statements of record.

Exchange Act Rule 13a-11(c) adds that failing to file an 8-K required solely under Items 1.01, 1.02, 1.05, 2.03, 2.04, 2.05, 2.06, 4.02(a), 5.02(e) or 6.03 is not by itself a violation of Rule 10b-5. The duty to report still exists.

The 10-K catches what the 8-Ks missed

Item 9B of Form 10-K, "Other Information", requires a company to disclose any information that should have been reported on an 8-K during the fourth quarter but was not. If it is disclosed there, it does not have to be repeated on an 8-K. Some companies also use Item 9B for events after year end, stating that the disclosure is made in lieu of an 8-K.

The flow also runs backwards. If a company concludes that previously issued annual financial statements should no longer be relied upon, it reports that on an 8-K under Item 4.02, and the restated figures normally follow in an amended 10-K or the next annual report. And General Instruction B.4 of Form 8-K notes that agreements need not be attached to an 8-K unless the item requires it, but they must still be filed as exhibits to registration statements and periodic reports under Item 601 of Regulation S-K, which is why a 10-K exhibit index often cites earlier 8-Ks.

A real pair: one year, three filings

Fennec Pharmaceuticals (FENC) has a calendar fiscal year and checks the non-accelerated filer box on its 10-K cover.

The event. On Thursday, November 13, 2025, the company entered into an underwriting agreement for 4,666,667 common shares at $7.50, with a 30-day option for 700,000 more. The Item 1.01 8-K was filed on Monday, November 17. Friday, November 14 was business day 1 and Monday was day 2. The four-business-day deadline was Wednesday, November 19.

The annual figures. The 10-K's Note 6 reports the same offering after the fact: 5,367 thousand shares including the 700 thousand option shares, for gross proceeds of about $40.25 million. That matches the 8-K: 4,666,667 + 700,000 = 5,366,667 shares, and 5,366,667 × $7.50 = $40,250,002.

The earnings release against the 10-K. On Tuesday, March 24, 2026, the company furnished its full-year results under Item 2.02. The 10-K followed on Friday, March 27, four days before the 90-day deadline of March 31, 2026 (31 + 28 + 31 days after December 31).

From the filing

Form 8-K
“The selected financial data presented below is derived from our unaudited condensed consolidated financial statements, which were prepared in accordance with U.S. generally accepted accounting principles.”

What Signal8 extracts:Earnings release basis: unaudited

Form 8-K · filed 2026-03-24 · accession 0001104659-26-033885

Several figures changed between the two documents:

FY2025, $ thousands8-K release (Mar 24)10-K (Mar 27)Change
Product sales, net44,64244,6420
General and administrative28,75628,294-462
Loss before income tax(10,098)(9,635)+463
Income tax0(106)-106
Net loss(10,098)(9,741)+357
Net loss per share(0.35)(0.34)+0.01

Revenue did not change; expenses and tax did. This guide does not infer why. The release was labelled unaudited, and the audited 10-K is the version that was filed.

How to check a company on Signal8

The form texts are on sec.gov: Form 8-K and Form 10-K. Rule 13a-11 is on eCFR.

FAQ

Is an 8-K earnings release audited?

Normally not. An Item 2.02 release reports results the company has prepared, and many releases say outright that the figures are unaudited. The audit opinion arrives with the 10-K, whose Item 8 financial statements must meet Regulation S-X and carry the independent auditor's report. A release can come out days or weeks before the 10-K, so its figures are the company's numbers before the annual report is filed, not an audited version.

Why can the earnings release and the 10-K show different numbers?

The release is prepared before the annual report is finalized and is usually unaudited. Between the two, the company can still record adjustments to expenses, tax or other lines. When the figures differ, the 10-K is the filed version. A difference by itself does not establish an error; for previously issued statements that should no longer be relied upon, the disclosure is an 8-K under Item 4.02.

Can something appear in a 10-K that was never in an 8-K?

Yes. Item 9B of Form 10-K requires disclosure of any information that should have been reported on an 8-K during the fourth quarter but was not, and once disclosed there it need not be repeated on an 8-K. More broadly, the 10-K covers the whole business, including risks, legal proceedings and financial detail that never triggered any 8-K item.

Does a 10-K replace the 8-Ks a company filed during the year?

No. The 8-Ks stay on EDGAR as the record of what was disclosed and when. The 10-K summarizes the year and often refers back to them, for example through exhibits incorporated by reference to an earlier 8-K. It does not withdraw or amend those reports; it gives its own complete annual picture alongside them.

See it on DilutionScan

Companies DilutionScan covers, with the instruments read from their SEC filings. Open one to see each instrument and the filing it came from.

Terms in this guide

Form 8-K
A Form 8-K is the SEC current report a public company files, generally within four business days, to disclose material events such as agreements, offerings, executive changes and listing notices.
Form 10-Q
A Form 10-Q is the quarterly report a US public company files for each of its first three fiscal quarters, with unaudited financial statements, due 40 or 45 days after quarter end.

Sources

  • SEC accession 0001104659-25-112912 Fennec Pharmaceuticals 8-K, filed 2025-11-17, Item 1.01: underwriting agreement dated November 13, 2025 for 4,666,667 common shares at $7.50, plus a 700,000-share option
  • SEC accession 0001104659-26-033885 Fennec Pharmaceuticals 8-K, filed 2026-03-24, Item 2.02 furnished: FY2025 release, unaudited; G&A $28,756K, income tax nil, net loss $10,098K, $(0.35) per share
  • SEC accession 0001104659-26-036182 Fennec Pharmaceuticals 10-K, filed 2026-03-27, non-accelerated filer: audited FY2025 G&A $28,294K, income tax $(106)K, net loss $9,741K, $(0.34) per share; Note 6 offering of 5,367K shares

Check any ticker for dilution

DilutionScan reads each covered company's SEC filings and lists its warrants, convertibles, ATM programs, shelves and S-1s on one page, with a dilution rating and cash runway.

This guide is from the Signal8 Academy, the research team behind DilutionScan. Educational content only. DilutionScan and Signal8 are not broker-dealers or investment advisers, and nothing here is a recommendation to buy or sell any security.

DilutionScan ProEvery instrument in full · $59/mo